Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
Expert Review of Proteomics
|
October 11, 2018
Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future
Mariaelena Pierobon, Emanuel F Petricoin, Julia D Wulfkuhle
Nature Reviews. Cancer
|
April 3, 2003
Proteomic applications for the early detection of cancer
Julia D Wulfkuhle, Lance A Liotta, Emanuel F Petricoin
Current Opinion in Molecular Therapeutics
|
June 28, 2005
Reverse-phase protein microarrays for tissue-based analysis
Runa Speer, Julia D Wulfkuhle, Lance A Liotta, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
May 15, 2017
Innovations in Clinical Trial Design in the Era of Molecular Profiling
Julia D Wulfkuhle, Alexander Spira, Kirsten H Edmiston, et al.
JAMA
|
April 8, 2004
STUDENTJAMA. Molecular technologies for personalized cancer management
Rani K Hasan, Julia D Wulfkuhle, Lance A Liotta, et al.
Nature Clinical Practice. Oncology
|
May 10, 2006
Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays
Julia D Wulfkuhle, Kirsten H Edmiston, Lance A Liotta, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
January 26, 2008
Reverse phase protein microarrays for monitoring biological responses
Virginia Espina, Julia D Wulfkuhle, Valerie S Calvert, et al.
Advances in Experimental Medicine and Biology
|
August 12, 2003
Proteomic approaches to the diagnosis, treatment, and monitoring of cancer
Julia D Wulfkuhle, Cloud P Paweletz, Patricia S Steeg, et al.
International Journal of Cancer
|
February 14, 2012
Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines
Ton van Agthoven, Marcia F E Godinho, Julia D Wulfkuhle, et al.
Molecular Cancer Therapeutics
|
June 30, 2011
Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer
Daniel Gioeli, Winfried Wunderlich, Judith Sebolt-Leopold, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
Expert Review of Proteomics
|
October 11, 2018
Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future
Mariaelena Pierobon, Emanuel F Petricoin, Julia D Wulfkuhle
Nature Reviews. Cancer
|
April 3, 2003
Proteomic applications for the early detection of cancer
Julia D Wulfkuhle, Lance A Liotta, Emanuel F Petricoin
Current Opinion in Molecular Therapeutics
|
June 28, 2005
Reverse-phase protein microarrays for tissue-based analysis
Runa Speer, Julia D Wulfkuhle, Lance A Liotta, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
May 15, 2017
Innovations in Clinical Trial Design in the Era of Molecular Profiling
Julia D Wulfkuhle, Alexander Spira, Kirsten H Edmiston, et al.
JAMA
|
April 8, 2004
STUDENTJAMA. Molecular technologies for personalized cancer management
Rani K Hasan, Julia D Wulfkuhle, Lance A Liotta, et al.
Nature Clinical Practice. Oncology
|
May 10, 2006
Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays
Julia D Wulfkuhle, Kirsten H Edmiston, Lance A Liotta, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
January 26, 2008
Reverse phase protein microarrays for monitoring biological responses
Virginia Espina, Julia D Wulfkuhle, Valerie S Calvert, et al.
Advances in Experimental Medicine and Biology
|
August 12, 2003
Proteomic approaches to the diagnosis, treatment, and monitoring of cancer
Julia D Wulfkuhle, Cloud P Paweletz, Patricia S Steeg, et al.
International Journal of Cancer
|
February 14, 2012
Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines
Ton van Agthoven, Marcia F E Godinho, Julia D Wulfkuhle, et al.
Molecular Cancer Therapeutics
|
June 30, 2011
Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer
Daniel Gioeli, Winfried Wunderlich, Judith Sebolt-Leopold, et al.
Page
of 5